Phenotype standardization for drug-induced kidney disease

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMEHTA, Ravindra L.
dc.contributor.authorAWDISHU, Linda
dc.contributor.authorDAVENPORT, Andrew
dc.contributor.authorMURRAY, Patrick T.
dc.contributor.authorMACEDO, Etienne
dc.contributor.authorCERDA, Jorge
dc.contributor.authorCHAKARAVARTHI, Raj
dc.contributor.authorHOLDEN, Arthur L.
dc.contributor.authorGOLDSTEIN, Stuart L.
dc.date.accessioned2019-05-30T13:45:22Z
dc.date.available2019-05-30T13:45:22Z
dc.date.issued2015
dc.description.abstractDrug-induced kidney disease is a frequent cause of renal dysfunction; however, there are no standards to identify and characterize the spectrum of these disorders. We convened a panel of international, adult and pediatric, nephrologists and pharmacists to develop standardized phenotypes for drug-induced kidney disease as part of the phenotype standardization project initiated by the International Serious Adverse Events Consortium. We propose four phenotypes of drug-induced kidney disease based on clinical presentation: acute kidney injury, glomerular, tubular, and nephrolithiasis, along with the primary and secondary clinical criteria to support the phenotype definition, and a time course based on the KDIGO/AKIN definitions of acute kidney injury, acute kidney disease, and chronic kidney disease. Establishing causality in drug-induced kidney disease is challenging and requires knowledge of the biological plausibility for the specific drug, mechanism of injury, time course, and assessment of competing risk factors. These phenotypes provide a consistent framework for clinicians, investigators, industry, and regulatory agencies to evaluate drug nephrotoxicity across various settings. We believe that this is the first step to recognizing drug-induced kidney disease and developing strategies to prevent and manage this condition.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipInternational Serious Adverse Events Consortium
dc.identifier.citationKIDNEY INTERNATIONAL, v.88, n.2, p.226-234, 2015
dc.identifier.doi10.1038/ki.2015.115
dc.identifier.eissn1523-1755
dc.identifier.issn0085-2538
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/31931
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUPeng
dc.relation.ispartofKidney International
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright NATURE PUBLISHING GROUPeng
dc.subjectacute kidney injuryeng
dc.subjectadverse reactioneng
dc.subjectdrugseng
dc.subjectglomerulonephritiseng
dc.subjecthypersensitivityeng
dc.subjectnephrotoxicityeng
dc.subject.otherexperienceeng
dc.subject.otherinjuryeng
dc.subject.otherakieng
dc.subject.wosUrology & Nephrologyeng
dc.titlePhenotype standardization for drug-induced kidney diseaseeng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryÍndia
hcfmusp.affiliation.countryInglaterra
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryIrlanda
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisogb
hcfmusp.affiliation.countryisoie
hcfmusp.affiliation.countryisoin
hcfmusp.author.externalMEHTA, Ravindra L.:Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
hcfmusp.author.externalAWDISHU, Linda:Univ Calif San Diego, Skaggs Sch Pharm, La Jolla, CA 92093 USA
hcfmusp.author.externalDAVENPORT, Andrew:Royal Free Hosp, London NW3 2QG, England; UCL, Sch Med, UCL Ctr Nephrol, London W1N 8AA, England
hcfmusp.author.externalMURRAY, Patrick T.:Univ Coll Dublin, Hlth Sci Ctr, Sch Med & Med Sci, Dublin 2, Ireland
hcfmusp.author.externalCERDA, Jorge:Albany Med Coll, Albany, NY 12208 USA
hcfmusp.author.externalCHAKARAVARTHI, Raj:Care Hosp, Hyderabad, Telangana, India
hcfmusp.author.externalHOLDEN, Arthur L.:Int Serious Adverse Event Consortium, Chicago, IL USA
hcfmusp.author.externalGOLDSTEIN, Stuart L.:Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH USA
hcfmusp.citation.scopus135
hcfmusp.contributor.author-fmusphcETIENNE MARIA VASCONCELLOS DE MACEDO
hcfmusp.description.beginpage226
hcfmusp.description.endpage234
hcfmusp.description.issue2
hcfmusp.description.volume88
hcfmusp.origemWOS
hcfmusp.origem.pubmed25853333
hcfmusp.origem.scopus2-s2.0-84938552326
hcfmusp.origem.wosWOS:000358783000006
hcfmusp.publisher.cityNEW YORKeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAithal GP, 2011, CLIN PHARMACOL THER, V89, P806, DOI 10.1038/clpt.2011.58eng
hcfmusp.relation.referenceK.D.I.G.O.K.A.K.I.W. Group, 2012, KIDNEY INT, V2, P1eng
hcfmusp.relation.referenceKoyner JL, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-105eng
hcfmusp.relation.referenceMcCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297eng
hcfmusp.relation.referenceMehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.xeng
hcfmusp.relation.referenceMoffett BS, 2011, CLIN J AM SOC NEPHRO, V6, P856, DOI 10.2215/CJN.08110910eng
hcfmusp.relation.referenceNARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154eng
hcfmusp.relation.referencePark YH, 2005, PEDIATR NEPHROL, V20, P1126, DOI 10.1007/s00467-005-1915-8eng
hcfmusp.relation.referenceSelby NM, 2012, CLIN J AM SOC NEPHRO, V7, P533, DOI 10.2215/CJN.08970911eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicationa4daecbb-892e-4e32-9206-2e34adb151ab
relation.isAuthorOfPublication.latestForDiscoverya4daecbb-892e-4e32-9206-2e34adb151ab
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MEHTA_Phenotype_standardization_for_druginduced_kidney_disease_2015.PDF
Tamanho:
314.16 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - ODS/03